UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. ____)*

I-MAB
(Name of Issuer)
Ordinary shares, par value US\$0.0001 per share
(Title of Class of Securities)
44975P103**
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- o Rule 13d-1(c)
- x Rule 13d-1(d)
- * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
- ** There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 44975P103 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "IMAB." Each 10 ADSs represents 23 Ordinary Shares.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

February 9, 2021.

1.	Names of Re I.R.S. Identif		ersons. os. of above persons (entities only).	
	Kaijin	g Yan		
2.	Check the Ap	ppropriate	Box if a Member of a Group (See Instructions)	(a) o (b) o
3.	SEC Use On	ly		
4.	Citizenship o	or Place of	f Organization	
	PRC			
	Number of	5.	Sole Voting Power 13,655,240	
	Shares Beneficially Owned by	6.	Shared Voting Power 0	
	Each Reporting Person	7.	Sole Dispositive Power 13,655,240	
	With:	8.	Shared Dispositive Power 0	
9.	Aggregate A	mount Be	eneficially Owned by Each Reporting Person	
	13,655	5,240 (1)		
10.	Check if the	Aggregate	e Amount in Row (9) Excludes Certain Shares	0
11.	Percent of Cl	lass Repre	esented by Amount in Row (9)	
	8.3%	2)		
12.	Type of Repo	orting Per	son (See Instructions)	
	IN			
Dev cont Lim Tasl reco	elopment Co., L rols Tasly Holdi ited. Tasly Pharr y Biopharm Lim rd owner of 712.	td controling Group naceutical nited. Tasl ,243 Ordin	of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excluding 4,03	roup Co., Ltd. national BioInv One sole shareholder of linary Shares and the 6,868 ordinary
			nk of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awa	

share incentive plans of I-Mab). as reported to be outstanding in the Company's Form 424(B)(5) filed with the Securities Exchange Commission on

1.	Names of Re I.R.S. Identif		ersons. os. of above persons (entities only).	
	Tianjir	ı Fuhuad	e Science & Technology Development Co., Ltd.	
2.	Check the Ap	ppropriat	e Box if a Member of a Group (See Instructions)	(a) o (b) o
3.	SEC Use On	ly		
4.	Citizenship o	or Place c	f Organization	
	PRC			
	Number of Shares Beneficially Owned by Each Reporting Person With:	5.6.7.8.	Sole Voting Power 13,655,240 Shared Voting Power 0 Sole Dispositive Power 13,655,240 Shared Dispositive Power 0	
9.		mount B	eneficially Owned by Each Reporting Person	
10.	Check if the	Aggrega	e Amount in Row (9) Excludes Certain Shares	0
11.	Percent of Cl	_	esented by Amount in Row (9)	
12.	Type of Repo	orting Pe	son (See Instructions)	
Indu and Co., 12,9	stry Investment Tasly Internation Ltd. is the sole s 42,997 Ordinary The ownership poes issued to the o	Group C nal BioIn shareholo Shares a ercentage deposit b	A Technology Development Co., Ltd controls Tianjin Tasly Health Industry Ir co., Ltd. controls Tasly Holding Group Co., Ltd. Tasly Holding Group Co., Ltd. Tasly Holding Group Co., Ltd. Controls Tasly Biopharm er of Tasly Biopharm Limited. Tasly Biopharm Limited and Tasly Internation and the record owner of 712,243 Ordinary Shares. of the Reporting Person is calculated based on 165,477,620 ordinary shares can find the record to be controlled in the Company of Taxley (214(D)(5) filed with	d. controls Tasly Pharmaceutical Group Co., Ltd. naceuticals Co., Ltd Tasly Biopharmaceuticals all BioInv One Limited are the record owner of outstanding (excluding 4,036,868 ordinary e exercise or vesting of awards granted under the
	uary 9, 2021.	, OI 1-1VId	b). as reported to be outstanding in the Company's Form 424(B)(5) filed with	the occurrees Exchange Commission on

1.	Names of Re I.R.S. Identif		ersons. os. of above persons (entities	s only).		
	Tianjir	n Tasly He	ealth Industry Investment Gro	oup Co., Ltd.		
2.	Check the Ap	ppropriate	Box if a Member of a Group		(a) (b) (c)	
3.	SEC Use On	ly				
4.	Citizenship o	or Place of	Organization			
	PRC					
	Number of	5.	Sole Voting Power 13,655,240			
	Shares Beneficially Owned by	6.	Shared Voting Power 0			
	Each Reporting Person	7.	Sole Dispositive Power 13,655,240			
	With:	8.	Shared Dispositive Powe 0	er		
9.	Aggregate A	mount Be	neficially Owned by Each Re	eporting Person		
	13,655	5,240 ⁽⁵⁾				
10.	Check if the	Aggregat	e Amount in Row (9) Exclude	les Certain Shares	(0
11.	Percent of Cl	lass Repre	esented by Amount in Row (9	9)		
	8.3% (6)				
12.	Type of Repo	orting Per	son (See Instructions)			
Pha Ltd.	rmaceutical Grou . Tasly Biopharn	ıp Co., Lt naceutical	d. and Tasly International Bios s Co., Ltd. is the sole shareho	td. controls Tasly Holding Group Co., Ltd Tasly Holding Group Co., Ltd. control oInv One Limited. Tasly Pharmaceutical Group Co., Ltd. controls Tasly Biopharm older of Tasly Biopharm Limited. Tasly Biopharm Limited and Tasly International es and the record owner of 712,243 Ordinary Shares.	naceut	icals Co.,
shar shar	es issued to the o	deposit ba	nk of I-Mab for bulk issuance	alculated based on 165,477,620 ordinary shares outstanding (excluding 4,036,868 te of ADSs reserved for future issuances upon the exercise or vesting of awards graing in the Company's Form 424(B)(5) filed with the Securities Exchange Commission	anted	under the

1.	Names of Re I.R.S. Identif		ersons. os. of above persons (entities only).	
	Tasly I	Holding C	Group Co., Ltd.	
2.	Check the Ap	ppropriate	e Box if a Member of a Group (See Instructions)	(a) o (b) o
3.	SEC Use On	y		
4.	Citizenship o	r Place o	f Organization	
	PRC			
	Number of	5.	Sole Voting Power 13,655,240	
	Shares Beneficially Owned by	6.	Shared Voting Power 0	
	Each Reporting Person	7.	Sole Dispositive Power 13,655,240	
	With:	8.	Shared Dispositive Power 0	
9.	Aggregate A	mount Be	eneficially Owned by Each Reporting Person	
	13,655	,240 (7)		
10.	Check if the	Aggregat	e Amount in Row (9) Excludes Certain Shares	o
11.	Percent of Cl	ass Repre	esented by Amount in Row (9)	
	8.3% (3)		
12.	Type of Repo	orting Per	son (See Instructions)	
	СО			
Co., Biop	Ltd. controls Ta	sly Bioph	Ltd. controls Tasly Pharmaceutical Group Co., Ltd. and Tasly International BioInv One Limited. Tasly Pharmaceuticals Co., Ltd Tasly Biopharmaceuticals Co., Ltd. is the sole shareholder of Tasly Biopharm Limiternational BioInv One Limited are the record owner of 12,942,997 Ordinary Shares and the record own	mited. Tasly

⁽⁸⁾ The ownership percentage of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excluding 4,036,868 ordinary shares issued to the deposit bank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of I-Mab). as reported to be outstanding in the Company's Form 424(B)(5) filed with the Securities Exchange Commission on February 9, 2021.

1.	Names of Re I.R.S. Identif		Persons. Nos. of above persons (entities only).	
	Tasly I	Pharmace	eutical Group Co., Ltd.	
2.	Check the Ap	ppropriate	•) o) o
3.	SEC Use On	ly		
4.	Citizenship o	or Place o	of Organization	
	PRC			
	Number of Shares Beneficially Owned by Each Reporting Person With:	5. 6. 7. 8.	Sole Voting Power 12,942,997 Shared Voting Power 0 Sole Dispositive Power 12,942,997 Shared Dispositive Power 0	
9.		mount Be	Beneficially Owned by Each Reporting Person	
10.	Check if the	Aggregat	ate Amount in Row (9) Excludes Certain Shares	0
11.	Percent of Cl	_	resented by Amount in Row (9)	
12.	Type of Repo	orting Per	erson (See Instructions)	
			Dup Co., Ltd. controls Tasly Biopharmaceuticals Co., Ltd Tasly Biopharmaceuticals Co., Ltd. is the sole shareholo opharm Limited is the record owner of 12,942,997 Ordinary Shares.	der of Tasly
shar shar	es issued to the o	deposit ba	ge of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excluding 4,036,868 coank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards gran ab). as reported to be outstanding in the Company's Form 424(B)(5) filed with the Securities Exchange Commission	ted under the

1.	Names of Re I.R.S. Identif		ersons. os. of above persons (entities only).		
	Tasly I	Biopharm	aceuticals Co., Ltd.		
2.	Check the Ap	ppropriate	e Box if a Member of a Group (See Instructions)	(a) o (b) o	
3.	SEC Use On	ly			
4.	Citizenship o	or Place o	f Organization		
-	PRC				
	Number of	5.	Sole Voting Power 12,942,997		
	Shares Beneficially Owned by	6.	Shared Voting Power 0		
	Each Reporting Person	7.	Sole Dispositive Power 12,942,997		
	With:	8.	Shared Dispositive Power 0		
9.	Aggregate A	mount Be	eneficially Owned by Each Reporting Person		
	12,942	2,997 (11)			
10.	Check if the	Aggregat	e Amount in Row (9) Excludes Certain Shares	0	
11.	Percent of Cl	lass Repro	esented by Amount in Row (9)		
	7.8% (12)			
12.	Type of Repo	orting Per	rson (See Instructions)		
	СО				
	Tasly Biopharm	aceutical	s Co., Ltd. is the sole shareholder of Tasly Biopharm Limited. Tasly Biopharm Limited is the record	owner of 12,942,997	
shar shar	es issued to the o	deposit ba	ge of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excludin ank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of b). as reported to be outstanding in the Company's Form 424(B)(5) filed with the Securities Exchange.	f awards granted under t	the

1.	Names of Re I.R.S. Identif		Persons. Ios. of above persons (entities only).		
	Tasly E	Biopharm	a Limited		
2.	Check the Ap	propriate	e Box if a Member of a Group (See Instructions)	(a) (b)	0 0
3.	SEC Use Onl	у			
4.	Citizenship o	r Place o	f Organization		
	British	Virgin Is	slands		
	Number of Shares Beneficially	5. 6.	Sole Voting Power 12,942,997 Shared Voting Power 0		
	Owned by Each Reporting Person With:	7. 8.	Sole Dispositive Power 12,942,997 Shared Dispositive Power 0		
9.	Aggregate Ar		eneficially Owned by Each Reporting Person		
10.	Check if the	Aggregat	te Amount in Row (9) Excludes Certain Shares		0
11.	Percent of Cl		esented by Amount in Row (9)		
12.	Type of Repo	orting Per	rson (See Instructions)		
share share	es issued to the d	leposit ba	ge of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excluding ank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting ob). as reported to be outstanding in the Company's Form 424(B)(5) filed with the Securities Exchanges.	f awards grante	d under the

1.	Names of Rep	porting P	ersons. os. of above persons (entities only).		
	Tasly I	nternatio	nal BioInv One Limited		
2.	Check the Ap	propriate	e Box if a Member of a Group (See Instructions)	(a) (b)	0 0
3.	SEC Use Onl	у			
4.	Citizenship o	r Place of	f Organization		
	Cayma	n Islands			
	Number of Shares Beneficially Owned by	5. 6.	Sole Voting Power 712,243 Shared Voting Power 0		
	Each Reporting Person With:	7.	Sole Dispositive Power 712,243		
	with.	8.	Shared Dispositive Power 0		
9.	Aggregate Aı	mount Be	eneficially Owned by Each Reporting Person		
	712,24	3			
10.	Check if the A	Aggregate	e Amount in Row (9) Excludes Certain Shares		0
11.	Percent of Cl. 0.4% (1		esented by Amount in Row (9)		
12.	Type of Repo	orting Per	son (See Instructions)		
share share	es issued to the d	leposit ba	ge of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excluding the of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of the object of the company's Form 424(B)(5) filed with the Securities Exchanges.	f awards grante	d under the

Item 1.

(a) Name of Issuer:

I-MAB

(b) Address of Issuer's Principal Executive Offices:

Suite 802, West Tower, OmniVision 88 Shangke Road, Pudong District Shanghai, 201210 People's Republic of China

Item 2.

- (a) Name of Person Filing:
 - I. Kaijing Yan
 - II. Tianjin Fuhuade Science & Technology Development Co., Ltd.
 - III. Tianjin Tasly Health Industry Investment Group Co., Ltd.
 - IV. Tasly Holding Group Co., Ltd.
 - V. Tasly Pharmaceutical Group Co., Ltd.
 - VI. Tasly Biopharmaceuticals Co., Ltd.
 - VII. Tasly Biopharm Limited
 - VIII. Tasly International BioInv One Limited
- (b) Address of Principal Business Office or, if none, Residence:

I, II, III, IV & V.

Tasly-TCM Garden No. 2 Pujihe East Road Beichen district, Tianjin P.R.China.

VI. & VII.

Building 1&2, No. 280, Juli Road China (Shanghai) Pilot Free Trade Zone P.R.China.

VIII.

Room 2302, 23/F, Far East Finance Center 16 Harcourt Road, Admiralty Hong Kong

(c) Citizenship:

I, II, III, IV, V. &VI People's Republic of China VII. British Virgin Islands
VIII. Cayman Islands

(d) Title of Class of Securities:

Ordinary shares, par value of \$0.0001 per share

(e) CUSIP Number:

44975P103

There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 44975P103 has been assigned to the American Depositary Shares("ADSs") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "IMAB." Each 10 ADSs represents 23 Ordinary Shares.

Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

Not applicable

Item 4. Ownership

(a) Amount beneficially owned:

The information required by Items 4(a) is set forth in Row 9 of the cover page for each Reporting Person and is incorporated herein by reference.

(b) Percent of class:

The information required by Items 4(a) is set forth in Row 11 of the cover page for each Reporting Person and is incorporated herein by reference.

(c) Number of shares as to which the person has:

The information required by Items 4(c) is set forth in Rows 5-8 of the cover page for each Reporting Person and is incorporated herein by reference.

Kaijing Yan is the controlling shareholder of Tianjin Fuhuade Science & Technology Development Co., Ltd. Tianjin Fuhuade Science & Technology Development Co., Ltd. Controls Tianjin Tasly Health Industry Investment Group Co., Ltd. Tianjin Tasly Health Industry Investment Group Co., Ltd. controls Tasly Holding Group Co., Ltd. Tasly Holding Group Co., Ltd. controls Tasly Pharmaceutical Group Co., Ltd. and Tasly International BioInv One Limited. Tasly Pharmaceutical Group Co., Ltd. controls Tasly Biopharmaceuticals Co., Ltd. Tasly Biopharmaceuticals Co., Ltd. is the sole shareholder of Tasly Biopharm Limited. Tasly Biopharm Limited and Tasly International BioInv One Limited are the record owner of 12,942,997 Ordinary Shares and the record owner of 712,243 Ordinary Shares.

Item 5. Ownership of Five Percent or Less of a Class

Not applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item 10. Certifications

Not applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct

Date: February 16, 2021

Kaijing YAN

/S/ Kaijing YAN

Tianjin Fuhuade Science & Technology Development Co., Ltd.

By: /S/ Kaijing YAN

Name: Kaijing YAN Title: General Manger

Tianjin Tasly Health Industry Investment Group Co., Ltd.

By: /S/ Kaijing YAN

Name: Kaijing YAN Title: Director

Tasly Holding Group Co., Ltd.

By: /S/ Kaijing YAN

Name: Kaijing YAN
Title: Director

Tasly Pharmaceutical Group Co., Ltd.

By: /S/ Kaijing YAN

Name: Kaijing YAN

Title: Chairman of the Board of Directors

Tasly Biopharmaceuticals Co., Ltd.

By: /S/ Kaijing YAN

Name: Kaijing YAN

Title: Chairman of the Board of Directors

Tasly Biopharm Limited

By: /S/ Kaijing YAN

Name: Kaijing YAN
Title: Director

Tasly International BioInv One Limited

By:

/S/ Kaijing YAN
Name: Kaijing YAN
Title: Director

Exhibit Index

Exhibit No.		Exhibit
99.1		Joint Filing Agreement
	14	

JOINT FILING AGREEMENT

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Class A ordinary shares of I-MAB shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. Each of the undersigned acknowledges that each shall be responsible for the timely filing of amendments with respect to information concerning such undersigned reporting person, and for the completeness and accuracy of the information concerning such undersigned reporting person, contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that such reporting person knows or has reason to believe that such information is inaccurate. This Agreement may be executed in any number of counterparts and all of such counterparts taken together shall constitute one and the same instrument.

Date: February 16, 2021

Kaijing YAN

/S/ Kaijing YAN

Tianjin Fuhuade Science & Technology Development Co., Ltd.

By: /S/ Kaijing YAN

Name: Kaijing YAN Title: General Manger

Tianjin Tasly Health Industry Investment Group Co., Ltd.

By: /S/ Kaijing YAN

Name: Kaijing YAN Title: Director

Tasly Holding Group Co., Ltd.

By: /S/ Kaijing YAN

Name: Kaijing YAN
Title: Director

Tasly Pharmaceutical Group Co., Ltd.

By: /S/ Kaijing YAN

Name: Kaijing YAN

Title: Chairman of the Board of Directors

Tasly Biopharmaceuticals Co., Ltd.

By: /S/ Kaijing YAN

Name: Kaijing YAN

Title: Chairman of the Board of Directors

Tasly Biopharm Limited

By: /S/ Kaijing YAN

Name: Kaijing YAN
Title: Director

Tasly International BioInv One Limited

By:

/S/ Kaijing YAN
Name: Kaijing YAN
Title: Director